Answers are grounded in this paper and cite their sources.
Samples from prospectively followed recipients, their respective donors, and a cohort of random donors were used to evaluate the specificity and efficacy of a recombinant immunoblot assay (RIBA) as an adjunct to anti‐hepatitis C virus (HCV) testing by enzyme immunoassay (EIA). RIBA reacted (RIBA+) in 100 percent of patients who developed hepatitis associated with anti‐HCV seroconversion documented by EIA and in 100 percent of the EIA‐positive (EIA+) donors implicated in these cases. In contrast, RIBA reacted in none of 10 recipients who were EIA+ but did not develop hepatitis, in none of 7 EIA+ patients with hepatitis B or cytomegalovirus infection, in 33 percent of EIA+ donors who were not implicated in hepatitis transmission, and in 37 percent of EIA+ random donors. Hence, the vast majority of EIA+ individuals who have ancillary evidence of HCV infection react on RIBA, whereas the majority of EIA+ individuals in low‐risk settings do not react (RIBA− negative, or RIBA−). There was a strong association between RIBA reactivity and the presence of a surrogate marker (elevated alanine aminotransferase [ALT] and/or antibody to hepatitis B core antigen); 43 percent of RIBA+ implicated donors had a surrogate marker as compared to none of 14 EIA+, RIBA− donors. Among EIA+ random donors, 77 percent of those with a surrogate marker were RIBA+, as compared with 29 percent of those without a surrogate marker. In addition, in EIA+ donors, RIBA reactivity correlated with the extent of ALT elevation; 86 percent of those with an ALT > 135 IU per L were RIBA+ compared with 18 percent of those with an ALT < 30 IU per L. Among recipients of an EIAt, RIBAt blood unit, 73 percent developed hepatitisC and an additional 6 percent developed hepatitis, but were not positive for anti‐HCV. None o f 13 recipients of an E I A t, RIBA‐ unit developed hepatitis (p<0.00l). By using linked donor‐recipient sets, a RIBAt donor was found i n association with 75 percent of hepatitisC cases, which implies that these cases could have been prevented if anti‐HCV screening had been available at the time of the prospective study. Although considered supplemental rather than a confirmatory assay, RIBA correlates well with HCV infectivity and with surrogate markers of viral hepatitis. It sability to distinguish probable true‐positive E I A reactions from probable false‐positive reactions makes it a valuable adjunct t o blood donor noti fication, and it should be used prior to such notification whenever possible.
No takes yet. Share an insight, caveat, or question.
Alter et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: